Stereotactic radiosurgery (SRS) for brain metastases: a systematic review by Carsten Nieder et al.
Nieder et al. Radiation Oncology 2014, 9:155
http://www.ro-journal.com/content/9/1/155REVIEW Open AccessStereotactic radiosurgery (SRS) for brain
metastases: a systematic review
Carsten Nieder1*, Anca L Grosu2 and Laurie E Gaspar3Abstract
In many patients with brain metastases, the primary therapeutic aim is symptom palliation and maintenance of
neurologic function, but in a subgroup, long-term survival is possible. Local control in the brain, and absent or
controlled extracranial sites of disease are prerequisites for favorable survival. Stereotactic radiosurgery (SRS) is a
focal, highly precise treatment option with a long track record. Its clinical development and implementation by
several pioneering institutions eventually rendered possible cooperative group randomized trials. A systematic review
of those studies and other landmark studies was undertaken. Most clinicians are aware of the potential benefits of SRS
such as a short treatment time, a high probability of treated-lesion control and, when adhering to typical dose/volume
recommendations, a low normal tissue complication probability. However, SRS as sole first-line treatment carries a risk
of failure in non-treated brain regions, which has resulted in controversy around when to add whole-brain radiotherapy
(WBRT). SRS might also be prescribed as salvage treatment in patients relapsing despite previous SRS and/or WBRT. An
optimal balance between intracranial control and side effects requires continued research efforts.
Keywords: Brain metastases, Radiation treatment, Radiotherapy, Stereotactic radiosurgeryHistorically, treatment options for patients with brain
metastases from solid tumors were limited to surgery
and/or whole-brain radiotherapy (WBRT) supported by
corticosteroids if indicated, with few systemic therapies
available that were able to impact on extracranial metasta-
ses. Therefore, median survival after non-surgical manage-
ment typically was in the range of 3-4 months [1]. Both
intra- and extracranial disease progression was common,
resulting in complex clinical situations with components
of decreasing performance status (PS), neurological status,
and impaired organ function, e.g. from liver and lung me-
tastases. Few patients who relapsed in the brain received
salvage treatment such as reirradiation [2,3]. Partial brain
fields or repeat WBRT were available but the efficacy
of these salvage attempts was modest [4]. There was an
urgent need for new treatment approaches, and among
several avenues of research, clinical implementation of
single fraction stereotactic radiosurgery (SRS) during
the 1980s probably was the single most important
innovation. The neurosurgery field gets credit for the* Correspondence: carsten.nieder@nlsh.no
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unless otherwise stated.early exploration of SRS [5-7], but the evolution of
imaging, radiation treatment planning and delivery technol-
ogy had to occur before several dedicated research groups
were able to safely deliver SRS to patients with brain me-
tastases [8-11]. The present review, which is based on a
well defined method for identification of relevant studies,
focuses on recent developments.Methods
A systematic search of the citation database Scopus
(Elsevier B.V., www.scopus.com) by use of the terms
‘stereotactic AND brain’ and ‘radiosurgery’ was performed
on 17th January 2014. We did not use more specific search
terms in order to avoid missing relevant publications.
Articles were selected irrespective of language, year of
publication and article type (review, guideline, clinical
study, experimental study etc.), as described previously
[12]. In order to determine whether or not a given article
reported on SRS for brain metastases we accessed its
abstract. Then, all articles dealing with the subject of
this review were ranked by number of citations (field
‘times cited’ in the Scopus citation database) in order to
create a list of articles with the highest number of cita-
tions, referred to as landmark studies (list available onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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articles were reviewed for contents, study type (phase I,
II, III, retrospective etc.) and outcomes. Given that such
hitlists are dominated by older publications because
recent articles are less likely to have accumulated high
numbers of citations [13], separate searches were per-
formed that covered the years 2011 and 2012, respectively.
The authors also used their reference lists from previous
reviews [14-17] to cross-check for important studies
that might not have been cited as often as expected. In
addition, on 22nd March 2014 the database Medline/
PubMed was searched by the two terms mentioned above.
Results and discussion
Table 1 contains the 25 most-cited articles [18-42]. These
were published between 1990 and 2010. Of these, the pro-
spective randomized clinical trials acquired the highest
numbers of citations per year [18-20]. Most clinically rele-
vant aspects of SRS for brain metastases are represented
in the table, including the role of SRS alone compared toTable 1 Articles with most citations (ranked by absolute coun
Authors and year of publication Study description
Andrews et al. 2004 [18] RTOG 9508 randomised trial
Aoyama et al. 2006 [19] SRS ± WBRT randomised trial
Kondziolka et al. 1999 [20] WBRT ± SRS randomised trial
Flickinger et al. 1994 [21] SRS for solitary BM, multi institutio
Shaw et al. 2000 [22] RTOG protocol 90-05
Alexander et al. 1995 [23] Retrospective study
Auchter et al. 1996 [24] SRS for resectable single BM, multi
Chang et al. 2009 [25] SRS ± WBRT randomised trial
Sneed et al. 2002 [26] SRS ± WBRT, multi institutional
Sneed et al. 1999 [27] SRS ± WBRT, single institution
Pirzkall et al. 1998 [28] SRS ± WBRT, single institution
Sperduto et al. 2008 [29] Prognostic score, incl. RTOG 95-08
Mehta et al. 1992 [30] Prospective single arm, n = 40
Bindal et al. 1996 [31] SRS vs. resection
Engenhart et al. 1993 [32] Retrospective study
Mori et al. 1998 [33] SRS for melanoma BM
Hall & Brenner 1993 [34] Radiobiology of SRS
Shiau et al. 1997 [35] Local control after SRS
Aoyama et al. 2007 [36] Neurocognitive outcome, random
Muacevic et al. 1999 [37] SRS vs. resection
Chao et al. 2001 [38] Radionecrosis vs. relapse after SRS
Adler et al. 1992 [39] Retrospective study
Sanghavi et al. 2001 [40] Multi institutional, stratified for pro
Sperduto et al. 2010 [41] Prognostic score, diagnosis specific
O’Neill et al. 2003 [42] SRS vs. resection
RTOG: Radiation Therapy Oncology Group, SRS: stereotactic radiosurgery, WBRT: whSRS plus WBRT, the role of WBRT alone compared to
WBRT plus SRS, the role of SRS compared to surgery,
patient selection based on prognostic models, SRS for re-
current disease, radiobiology of SRS, and toxicity. Issues
related to the outcomes of different treatment planning
approaches and treatment units ranked among the top 50
rather than the top 25 articles [10,43-66]. The most cited
publications from the year 2011 did not cover any new
aspects [67-71]. However the 2012 articles focused on
new topics such as SRS to resection cavities in the postop-
erative setting, SRS in patients with more than 4 brain
metastases, and new systemic treatments in addition to
SRS [72-76]. Fractionated stereotactic radiotherapy was
not among the most-cited topics.
We will not discuss postoperative SRS in great detail,
because this investigational approach so far is not yet
supported by randomized trials [76]. Phase 2 data sug-
gests that postoperative SRS is associated with high rates
of local control, especially for non-superficial brain me-
tastases of limited size (<3 cm) [77]. Metastases ≥3 cmt)


























ole-brain radiotherapy, BM: brain metastases.
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highest risk of local failure. In a different study, patients
with breast cancer had the highest risk of leptomeningeal
progression following SRS (24% at 1 year) [78]. Head to
head comparisons of SRS to other types of postoperative
radiotherapy, including WBRT, are needed to conclusively
evaluate the pros and cons of SRS in this setting.
Some institutions have more than 25 years of experience
with SRS and have collected data on thousands of pa-
tients, often transfered to multi institutional databases. A
recent Japanese multi institutional prospective study in-
cluded 1194 patients (76% with lung cancer) [79]. Its aim
was to examine whether survival after SRS without WBRT
as initial treatment for patients with 5-10 brain metastases
(median 6) was non-inferior to that of patients with 2-4
lesions. Size limits were metastases <3 cm in longest
diameter, largest tumor <10 ml in volume, and total
cumulative volume ≤15 ml. Median survival was longest
in patients with one lesion (n = 455, 13.9 months). But pa-
tients with 2-4 lesions had comparable survival to patients
with 5-10 lesions (median survival 10.8 months, hazard
ratio 0.97, 95% confidence interval 0.81-1.18). This met
the pre-specified definition of non-inferiority, despite the
development of new lesions in >60% of patients. Further
salvage SRS was done in more than 40%, and 9% received
salvage WBRT. The delivery of further SRS or WBRT was
not significant different between the groups. Grade 3-4
adverse events occurred in up to 3% of patients in each
group. Only 8% of patients died from their brain disease.
As displayed in Table 2, SRS achieves high rates of
local progression-free survival of SRS-treated lesions and
its efficacy may be less influenced by histology or radio-
sensitivity than that of fractionated radiotherapy [63]. At
the same time, severe complications are observed in a
minority of patients. This is the primary reason for many
institutions to expand its utilization beyond the initial
target population, which often was defined as those with
1-3 lesions. The Japanese study [79] suggests that SRS isTable 2 Results of stereotactic radiosurgery (SRS) for brain m
Reference n (patients/lesions) Prescribed do
Pirzkall et al. 1998 [28] 236/311
Cho et al. 1998 [81] 73/136
Sneed et al. 1999 [27] 62/118a
43/117b
Varlotto et al. 2003 [82] 137/208
Andrews et al. 2004 [18] 164/269c N
Bhatnagar et al. 2006 [83] 205/4-18 lesions eachd
OS: overall survival in months; PFS: progression-free survival.
*Prescription isodose or point varied, some series included SRS plus WBRT.
aSRS only.
bSRS plus WBRT (no significant difference in OS and PFS between both groups).
cSRS plus WBRT.
dSRS plus/minus WBRT.reasonable for patients with up to 10 lesions. However, it
is also known that number of initial lesions predicts the
risk for development of new metastases and thus need
for salvage treatment (new course of SRS or WBRT).
Primary tumor type and extracranial disease status also
impact on distant brain failure risk. Based on these three
predictors, a nomogram was recently developed (n = 464
patients) [80]. Table 3 shows examples calculated accord-
ing to this model, which should be validated further.
Post-SRS adjuvant WBRT reduces intracranial relapses
and neurologic deaths but fails to improve the duration
of functional independence and overall survival [67,84].
The major obstacle against the general adoption of com-
bined SRS and WBRT is the fear of neurocognitive decline
after WBRT. Patients with limited survival expectation be-
cause of progressive, uncontrollable extracranial disease
should be managed with WBRT or best supportive care
rather than SRS [85,86].
First line SRS and the controversy around whole-brain
radiotherapy
Focal treatment such as SRS, improves the local control
observed with WBRT. In a small randomized study pri-
marily addressing this endpoint, patients with 2-4 brain
metastases (all ≤25 mm diameter) either received WBRT
alone (30 Gy in 12 fractions) or WBRT plus SRS [20].
The study was stopped at an interim evaluation following
accrual of just 27 patients. The rate of local failure at 1 year
was 100% after WBRT alone but only 8% in patients who
had boost SRS. In exploratory analysis, patients who
received WBRT alone lived a median of 7.5 months,
while those who received WBRT plus RS lived 11 months
(p = 0.22). With only 27 patients, possible survival differ-
ences cannot be adequately assessed. A different random-
ized study by the Radiation Therapy Oncology Group
(RTOG) enrolled 333 patients with 1-3 brain metastases
[18]. Maximum diameter of the largest lesion was 4 cm
and additional lesions could not exceed 3 cm. Minimumetastases
se (median; range [Gy])* Median OS (m) 1-year PFS (%)
20; 10-30 5.5 89
17.5; 6-50 7.8 80
18; 15-22 11.3 80
17.5; 15-22 11.1 86
16; 12-25 Not given 90
ot given; 15-24 6.5 82
16; 12-20 8.0 71
Table 3 Estimates of 6-month survival without distant brain failure based on a new nomogram [80]








Renal cell cancer 69% 67% 48% 46%
Malignant melanoma 57% 55% 32% 30%
Lung, adeno ca 74% 72% 55% 53%
Lung, squamous ca 58% 57% 33% 32%
Breast, Her-2 positive 73% 72% 53% 52%
Breast, Her-2 negative 67% 66% 43% 42%
Sex, age and race impact slightly on failure risk. The examples refer to approximately 55-60 years-old Caucasian females. The differences for male patients are in
the order of 1-2%.
BM: brain metastases.
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fractions in both groups. SRS boost dose was adjusted
to lesion size (24 Gy, 18 Gy and 15 Gy for lesions <
2 cm, > 2 cm but less than 3 cm, and > 3 cm but <
4 cm, respectively). Median survival was significantly
better after SRS boost in patients with single brain metas-
tasis. By multivariate analysis, survival was also improved
in recursive partitioning analysis (RPA) class I patients
(RPA details are provided in Table 4). SRS-treated patients
were more likely to have a stable or improved PS at
6 months (43% vs 27%, p = 0.03). Central imaging review
showed higher response rates at 3 months and better
control of the treated lesions at 1 year, p = 0.01. The risk
of developing a local recurrence was 43% greater with
WBRT alone. The addition of temozolomide or erlotinib
did not improve survival after WBRT and SRS in another
randomized RTOG trial, which included only patients
with non-small cell lung cancer [87].
After many years of controversy about the role of
combining WBRT with SRS and considerable variation in
practice [27,28], a Japanese group completed a prospective
randomized multicenter phase III study of SRS alone vs
combined SRS and WBRT [19]. The primary endpoint
was survival with an expected difference of 30%. The trial
included adult patients with Karnofsky PS >60 and aTable 4 Prognostic value of recursive partitioning analysis (R
Reference Number of patients
Gaspar et al. 1997 [88] 1200
Lorenzoni et al. 2004 [89] 110 (SRS)
Franzin et al. 2009 [90] 185 (SRS)
Likhacheva et al. 2012 [91] 251 (SRS)
Zindler et al. 2013 [92] 380 (SRS)
Sneed et al. 268 (SRS)
2002 [26] 301 (SRS + WBRT)
Median survival in months from different publications.
RPA class I: age <65 years, Karnofsky performance status ≥70, controlled primary tu
RPA class II: all other patients.
RPA class III: Karnofsky performance status <70.
SRS: stereotactic radiosurgery, WBRT: whole-brain radiotherapy.
*estimated from Kaplan-Meier graphs included in the publication.maximum of 4 brain metastases, none exceeding 3 cm
diameter. The patients were stratified by number of lesions
(1 vs 2-4), extracranial tumor activity (activ vs stable, i.e.
controlled for at least 6 months), and primary tumor (lung
cancer vs others). WBRT was given in 10 fractions of 3 Gy.
SRS dose varied with size of the lesion (up to 2 cm: 22-
25 Gy, > 2 cm: 18-20 Gy margin dose), and was reduced
by 30% if WBRT was given. The mean dose was 21.9 Gy
in the SRS alone arm and 16.6 Gy in the combined arm.
The combined arm contained 65 patients, the SRS arm
67 patients. Almost 50% of patients had a single lesion.
The SRS group contained slightly more patients with PS
90-100% (66 vs 52%) and patients without neurological
symptoms (70 vs 59%). However, the differences were not
statistically significant. Median survival was 7.5 months
after SRS plus WBRT and 8 months after SRS alone.
One-year survival in the combined treatment arm was
increased by 36%, but was not statistically significantly
different, possibly due to low patient numbers (38.5 vs
28.4%, p > 0.05). There was no significant difference in
the percentage of patients that died from predominantly
neurologic causes (23 vs 19%). Age, PS, extracranial disease
activity and status of the primary tumor were significant
prognostic factors on multivariate analysis. After SRS
alone, 2 patients developed serious late complicationsPA) classes








mor, no extracranial metastases.
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SRS plus WBRT, 3 patients developed a radionecrosis
and 3 signs of leukencephalopathy. The rate of actuarial
failure at 1 year was 47% after combined treatment, but
significantly greater at 76% after SRS alone (relative in-
crease of 62%; p < 0.001). New lesions developed in 42
vs 64% (p = 0.003). The risk was significantly higher in
patients presenting with 2-4 lesions before treatment,
those with active extracranial metastases and those with
PS 70-80. WBRT reduced the risk of failure at the site of
SRS from 27% to 11% after one year (p = 0.002).
The highly cited randomized trial from the M.D.
Anderson Cancer Center re-emphasized patient selection
issues as critical for overall survival [25]. In this trial,
patients with 1-3 newly diagnosed brain metastases were
randomly assigned to SRS plus WBRT or SRS alone, and
over an almost 7-year time frame, 58 patients were re-
cruited and stratified by RPA class, number of brain
metastases, and histology. The primary endpoint was
neurocognitive function: measured as a 5-point drop
compared with baseline in the Hopkins Verbal Learning
Test–Revised (HVLT-R) total recall at 4 months. An in-
terim analysis showed that there was a high probability
(96%) that patients assigned to receive SRS plus WBRT
were more likely to show a decline in learning and mem-
ory function at 4 months than patients assigned to receive
SRS alone. Further, at 4 months there were four deaths
(13%) in the group that received SRS alone, and eight
deaths (29%) in the group that received SRS plus WBRT,
and 73% of patients in the SRS plus WBRT group were
free from CNS recurrence at 1 year, compared with 27%
of patients who received SRS alone (p = 0.0003). These
differences in early death bring into question the
generalizability of the HVLT-R score results. It is well
known that a general disease-related decline due to
progression, especially in the pre-terminal phase will
cause a significant drop in neurocognitive function, and
its attribution to a single component, such as WBRT can
be misleading. Another potential confounder in evaluating
survival following SRS, with or without WBRT, is the initi-
ation of systemic treatment after radiation. Moreover, sev-
eral drug regimens are known to impact on brain function
[93]. Ongoing studies evaluate hippocampal sparing WBRT,
which aims at reducing dose to critical structures and
thereby risk of function decline, while maintaining im-
proved brain control [94,95]. In many clinical scenar-
ios, acceptable approaches include SRS or SRS plus
WBRT, as also summarized in an American Society for
Radiation Oncology (ASTRO) guideline [14] and recent
reviews [84,96].
Salvage SRS as reirradiation after whole-brain radiotherapy
The potential advantages of SRS as salvage treatment after
WBRT were realized early during the development of SRS[97]. The RTOG completed a prospective phase 1 clinical
trial (RTOG 90-05) of SRS in recurrent, previously irradi-
ated primary brain tumors and brain metastases. This was
a dose escalation trial, which included 100 patients with
brain metastases after prior WBRT to a median dose of
30 Gy [22]. Eligible patients had received first-line
radiotherapy at least 3 months prior to study entry, and
in the study, the actual median interval was 17 months.
Life expectancy was ≥3 months. Seventy-eight percent
of patients had single lesions. Dose was determined by
the maximum diameter of the tumor. Initial doses were
18 Gy for lesions ≤20 mm, 15 Gy for lesions measuring
21-30 mm, and 12 Gy for lesions measuring 31-40 mm.
Dose was prescribed to the 50-90% isodose line, which
was to encompass the entire enhancing target volume.
The dose was escalated in 3 Gy increments providing
there was not an excess of unacceptable toxicity. The
trial eventually defined the maximum acutely tolerable
SRS dose in this setting, except for lesions ≤20 mm
where the dose was not escalated beyond 24 Gy because
of investigators’ reluctance. While small lesions ≤20 mm
can be treated with up to 24 Gy to the margin of the
lesion, those that measure between 21 and 30 mm might
receive 18 Gy, and those that measure between 31 and
40 mm 15 Gy. Median survival was 7.5 months. Long-term
toxicity data for 64 brain metastases patients revealed four
patients developed radionecrosis requiring operation 5-14
months after SRS. This study therefore provides tentative
evidence that retreatment with SRS can produce extended
survival, but the incidence of necrosis must be factored in.
More recent data were derived from a retrospective
review of 106 patients irradiated for a median of 2 me-
tastases (range, 1-12) with a median dose of 21 Gy
(range, 12-24) prescribed to the 50% isodose [98]. With
a median follow-up of 10.5 months, local control was
83% at 6 months and 60% at 1 year. Median progression-
free survival was 6.2 months. Median overall survival was
11.7 months from salvage SRS, and 22 months from initial
diagnosis. Comparable outcomes were achieved in another
retrospective series that included 111 patients [99]. SRS
doses were usually prescribed according to the RTOG
90-05 guidelines. Median survival was 9.9 months. Twenty-
five percent of patients developed further local progression
in spite of salvage SRS. Poorer local control was observed
in lesions >2 cm, which usually had been treated with lower
radiation doses. Caballero et al. analyzed 310 patients [100].
The median number of brain metastases was 3, and interval
from WBRT to SRS 8 months. The median survival was
8.4 months overall and 12.0 vs. 7.9 months for single vs.
multiple lesions (p = 0.001). There was no relationship
between number of lesions and survival after excluding
patients with single metastases. Retrospective population-
based data from Canada suggested that salvage SRS after
WBRT was not associated with compromised survival
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ary experience with small numbers of patients exists for
salvage SRS after first-line SRS [102]. No definitive conclu-
sions regarding long-term safety have yet been published.
Prognostic staging systems
Patients with brain metastases have always presented
with a variable spectrum of number, size and location of
lesions, with different pattern and activity of extracranial
disease, and with a wide range of comorbidities and PS.
Estimation of prognosis is possible by using developed
staging systems (Table 4) [41,43,88,89]. For example the
RTOG developed the first RPA to define 3 classes of
patients with statistically different predicted survival [88].
Other systems for predicting survival include the score
index for radiosurgery (SIR) [43], basic score for brain
metastases (BSBM) [89], and diagnosis-specific graded
prognostic assessment (DS-GPA) score [41]. The latter
is an increasingly used 4-tiered system that provides
survival outcomes for patients with lung, breast, kidney
and gastrointestinal cancers as well as malignant melan-
oma. These patients were treated with a variety of different
approaches including but not limited to SRS. Their data
were also used to create a prognostic nomogram [103]. In a
recent study, symptomatic patients had an increased hazard
for all-cause mortality (hazard ratio, 1.4) and were more
likely to experience neurologic death after SRS (42% vs
20%, p < 0 .0001) [104]. Relative to asymptomatic patients,
symptomatic patients required more craniotomies (43% vs
5%, p < 0.0001) and were more likely to have RTOG grade
3 and 4 post-treatment symptoms (24% vs 5%; p < 0.0001).
Conclusions
SRS results in a high probability of treated-lesion control
and, when adhering to typical dose/volume recommen-
dations, a low normal tissue complication probability.
However, SRS as sole first-line treatment carries a risk
of failure in non-treated brain regions. SRS might also
be prescribed as salvage treatment in patients relapsing
despite previous SRS and/or WBRT. An optimal balance
between intracranial control and side effects requires
continued research efforts. Such efforts are also necessary
to integrate new systemic treatments and/or stereotactic
body radiotherapy, which aim at prolonged extracranial
disease control.
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